

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number  
**WO 2004/108692 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 241/20**,  
403/12, 417/12, 401/12, 413/12, A61K 31/4965, 31/497,  
A61P 11/06, 29/00

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
S-151 85 Södertälje (SE).

(21) International Application Number:  
PCT/SE2004/000850

(22) International Filing Date: 2 June 2004 (02.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:  
0301653-2 5 June 2003 (05.06.2003) SE

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HARRISON, Richard** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **METE, Antonio** [IT/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **TEOBALD, Barry** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **WALTERS, Iain** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4)

(57) Abstract: The invention relates to sulphonamide compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.



WO 2004/108692 A1

## NOVEL COMPOUNDS

5 The present invention relates to sulphonamide compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

10 Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small-secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. At the present time, the chemokine superfamily comprises three groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C), Cys-Cys (C-C)  
15 and Cys-X<sub>3</sub>-Cys (C-X<sub>3</sub>-C) families. The C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues. The C-X<sub>3</sub>-C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues.

20 The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).


25 The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (MIP-1 $\alpha$  and MIP-1 $\beta$ ), Thymus and Activation Regulated Chemokine (TARC, CCL17) and Macrophage Derived Chemokine (MDC, CCL22).

30 The C-X<sub>3</sub>-C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.

35 Studies have demonstrated that the actions of chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C

family) and CX<sub>3</sub>CR<sub>1</sub> for the C-X<sub>3</sub>-C family. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

- 5 The present invention therefore provides a compound of formula (I) and pharmaceutically acceptable salts, solvates or N-oxides thereof:



- 10 in which:

Ar<sup>1</sup> is phenyl or thienyl, each of which is optionally substituted by one to three substituents R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> selected from halogen, cyano, CF<sub>3</sub>, OCF<sub>3</sub>, OC<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkyl;

- 15 R<sup>4</sup> is C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group; or

OC<sub>1-6</sub> alkylR<sup>11</sup>, or OC<sub>2-6</sub> alkyl-X-R<sup>11</sup> where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR<sup>14</sup>R<sup>15</sup>, SR<sup>13</sup>, S(O)<sub>2</sub>R<sup>13</sup>, S(O)R<sup>13</sup> or COR<sup>13</sup>;

- 20 one of R<sup>5</sup> or R<sup>6</sup> is XCH<sub>2</sub>C<sub>1-4</sub> alkyl where the alkyl group is substituted at any position by the two groups R<sup>11</sup> and either NR<sup>14</sup>R<sup>15</sup> or hydroxy, or R<sup>5</sup>/R<sup>6</sup> is XR<sup>16</sup> where R<sup>16</sup> is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O, and R<sup>16</sup> is substituted by R<sup>11</sup>;
- 25

and the other is hydrogen, halogen, amino, NHC<sub>1-6</sub> alkyl, N(C<sub>1-6</sub> alkyl)<sub>2</sub>, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkyl optionally substituted by one or more fluoro or hydroxyl groups;

- 30 X is NR<sup>13</sup>, O, S, S(O), S(O)<sub>2</sub>, or a bond;

R<sup>11</sup> is an aryl group or a 5-7 membered heteroaromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, which aryl group or heteroaromatic ring can be optionally substituted by 1-3 groups selected from halogen, C(O)NR<sup>14</sup>R<sup>15</sup>, C(O)OR<sup>12</sup>,

hydroxy, =O, =S, CN, NO<sub>2</sub>, COR<sup>13</sup>, NR<sup>14</sup>R<sup>15</sup>, X(CH<sub>2</sub>)<sub>q</sub>NR<sup>14</sup>R<sup>15</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>14</sup>R<sup>15</sup>, (CH<sub>2</sub>)<sub>n</sub>OH, SR<sup>13</sup>, S(O)R<sup>13</sup>, S(O)<sub>2</sub>R<sup>13</sup>

C<sub>1-6</sub> alkyl-X-C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR<sup>14</sup>R<sup>15</sup>, SR<sup>13</sup>, S(O)R<sup>13</sup>, S(O)<sub>2</sub>R<sup>13</sup>; or

R<sup>11</sup> is C(O)NR<sup>14</sup>R<sup>15</sup>, C(O)OR<sup>12</sup>, CH<sub>2</sub>OR<sup>12</sup>

R<sup>12</sup> and R<sup>13</sup> are independently hydrogen or C<sub>1-6</sub> alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;

R<sup>14</sup> and R<sup>15</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, (CH<sub>2</sub>)<sub>q</sub>OH or (CH<sub>2</sub>)<sub>q</sub>NH<sub>2</sub>,

or R<sup>14</sup> and R<sup>15</sup> together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl-OH, or hydroxy; and

n is 1, 2, 3, 4 or 5; and

q is 2, 3, 4, 5 or 6,

- provided that where X is a bond then R<sup>5</sup>/R<sup>6</sup> is not XCH<sub>2</sub>C<sub>1-4</sub>alkylR<sup>11</sup>.

The term aryl includes phenyl and naphthyl. The term alkyl, whether alone or as part of another group, includes straight chain and branched chain alkyl groups. Examples of 5- to 7-membered heteroaromatic rings containing 1 to 4 heteroatoms include thienyl, furanyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl. Examples of saturated 4- to 8-membered rings containing 1 to 3 heteroatoms include morpholine, piperidine and azetidine. Substituents on any rings can be present in any suitable ring position including suitable substituents on nitrogen atoms.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.


Preferably Ar<sup>1</sup> is phenyl, more preferably substituted by one or more halogen atoms.

Preferred halogen groups for R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are chloro, bromo and fluoro. Preferably one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is hydrogen and the others are chloro, bromo or methyl. More preferably


5 R<sup>1</sup> and R<sup>2</sup> are chloro at the 2- and 3-positions of the phenyl ring and R<sup>3</sup> is hydrogen (i.e. 2,3-dichlorophenyl), R<sup>1</sup> and R<sup>3</sup> are chloro at the 2- and 4-positions of the phenyl ring and R<sup>2</sup> is hydrogen (i.e. 2,4-dichlorophenyl) or R<sup>1</sup> is chloro at the 2-position and R<sup>2</sup> is methyl at the 3-position of the phenyl ring and R<sup>3</sup> is hydrogen (i.e. 2-chloro-3-methylphenyl). Most preferably R<sup>1</sup> and R<sup>2</sup> are chloro at the 2- and 3-positions of the phenyl ring and R<sup>3</sup> is  
10 hydrogen (i.e. 2,3-dichlorophenyl).

Preferably R<sup>4</sup> is methoxy.

For R<sup>5</sup> examples of NR<sup>14</sup>R<sup>15</sup> include morpholine, pyrrolidine, NMe<sub>2</sub>, NH<sub>2</sub>, NHMe, and the  
15 groups below:



Examples of XCH<sub>2</sub>C<sub>1-4</sub> alkyl where the alkyl group is substituted at any position by the two  
20 groups R<sup>11</sup> and either NR<sup>14</sup>R<sup>15</sup> or hydroxy include SCH<sub>2</sub>CH(Ph)NH<sub>2</sub> and OCH<sub>2</sub>CH(pyridyl)OH. Examples of XR<sup>16</sup> where R<sup>16</sup> is substituted by R<sup>11</sup> include the groups below:



25 Preferably R<sup>5</sup> is XCH<sub>2</sub>CH(R<sup>11</sup>)NR<sup>14</sup>R<sup>15</sup> where R<sup>11</sup> is CO<sub>2</sub>Me or CONHMe or a 5 or 6-membered heterocycle and NR<sup>14</sup>R<sup>15</sup> is NH<sub>2</sub> or NHMe and X is S or O. More preferably R<sup>5</sup> is XCH<sub>2</sub>CH(R<sup>11</sup>)NR<sup>14</sup>R<sup>15</sup> where R<sup>11</sup> is CO<sub>2</sub>Me, 2-thiazole or C(O)NHMe, and NR<sup>14</sup>R<sup>15</sup> is  
30 NH<sub>2</sub> and X is S.

Preferably R<sup>6</sup> is hydrogen, chloro or methyl.

Preferably X is NR<sup>13</sup>, O, S, S(O) or S(O)<sub>2</sub>.

Preferred compounds of the invention include:

- 5 S-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester
- S-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester
- S-[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine
- (2*R*)-2-amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-
- methoxypyrazinyl]thio]propanamide
- 10 (2*R*)-2-amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-
- methoxypyrazinyl]thio]propanamide
- (2*R*)-2-amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N,N*-
- dimethylpropanamide
- N*-[5-[[[(2*R*)-2-amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichloro
- 15 benzenesulfonamide
- S*-[3-chloro-5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine,
- methyl ester
- S*-[3-chloro-5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine
- N*-[5-[[[(2*R*)-2-amino-3-hydroxypropyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-
- 20 dichlorobenzenesulfonamide
- S*-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine,
- methyl ester
- S*-[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine,
- N*-(2-Aminoethyl)-*S*-[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-
- 25 cysteine, ethyl ester
- N*-[5-[(2*R*)-2-amino-2-phenylethoxy]-3-methoxypyrazinyl]-2,3-
- dichlorobenzenesulfonamide
- 2,3-Dichloro-*N*-[5-[[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-
- benzenesulfonamide
- 30 2,3-Dichloro-*N*-[5-[[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-
- methoxypyrazinyl]-benzenesulfonamide, potassium salt
- 2,3-Dichloro-*N*-[5-[[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-
- benzenesulfonamide
- N*-[5-[[[2-amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-
- 35 dichlorobenzenesulfonamide
- 2,3-dichloro-*N*-[5-[[[2,3-dihydroxypropyl]thio]-3-methoxypyrazinyl] benzenesulfonamide

2,3-dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]  
benzenesulfonamide

2,3-dichloro-*N*-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]  
benzenesulfonamide

5 *N*-[5-[[2-amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro  
benzenesulfonamide

2,3-dichloro-*N*-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-  
methoxypyrazinyl]benzenesulfonamide

10 2,3-dichloro-*N*-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-  
methoxypyrazinyl]benzenesulfonamide

3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2*R*)-2-  
hydroxypropanoic acid, methyl ester

*N*-[5-[[2-amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-  
dichlorobenzenesulfonamide

15 *N*-[5-[[2-amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-  
dichlorobenzenesulfonamide

(2*R*)-2-amino-3-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-  
methoxypyrazinyl]thio]-*N*-methylpropanamide

(2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-  
20 methylpyrazinyl]thio]-*N*-methylpropanamide

*N*-[5-[[2-amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-  
dichlorobenzenesulfonamide

*N*-[5-[[2-*R*)-2-Amino-3-hydroxypropyl]oxy]-3-methoxypyrazinyl]-2,3-  
dichlorobenzenesulfonamide, monohydrochloride

25 2,3-Dichloro-*N*-[5-[[2-*S*)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-  
benzenesulfonamide

2,3-Dichloro-*N*-[5-[[2-*R*)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-  
benzenesulfonamide


*N*-[5-[[2-*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxypyrazinyl]-  
30 2,3-dichlorobenzenesulfonamide

*N*-[5-[[*(2R)*-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulfonamide

*N*-[5-[[*(2R)*-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

5 and pharmaceutically acceptable salts and solvates thereof.

According to the invention there is also provided a process for the preparation of compound (I) which comprises reaction of a compound of formula (II):




where Ar<sup>1</sup>, R<sup>4</sup> and R<sup>6</sup> are as defined above, P is a suitable protecting group (e.g. trimethylsilylethoxymethyl (SEM)) and X is a leaving group (e.g. chloro or bromo) with a compound R<sup>5</sup>-H in the presence of a base, and optionally thereafter,

- removing any protecting groups
- forming a pharmaceutically acceptable salt.

20 The reaction may conveniently be carried out in a solvent (e.g. acetonitrile) at room temperature using a base (e.g. caesium carbonate). The protecting group P is typically removed using an acid such as trifluoroacetic acid in a solvent such as dichloromethane at room temperature.

Compounds of formula (II) may be prepared from compounds of formula (III)






where  $\text{Ar}^1$ ,  $\text{R}^4$ ,  $\text{R}^6$  and X are as defined above by reaction with a suitable protecting reagent such as 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl). The reaction may be performed in a solvent such as dichloromethane in the presence of a base such as diisopropylamine at room temperature.

Compounds of formula (III) where  $\text{Ar}^1$ ,  $\text{R}^4$  and  $\text{R}^6$  are as defined in formula (I) or are protected derivatives thereof and X is a leaving group such as chloro or bromo may be prepared either:-


(a) from compounds of formula (IV):



(IV)

where  $\text{Ar}^1$  and  $\text{R}^6$  are as defined above and X and L are leaving groups such as chloro or bromo by reaction with a compound  $\text{R}^4\text{-H}$  in the presence of a suitable base. The compound  $\text{R}^4\text{-H}$  may be used as the solvent, such as methanol, in which case a suitable base would be sodium methoxide, and the reaction may be performed at a temperature between  $20^\circ\text{C}$  and  $100^\circ\text{C}$ , or


(b) from compounds of formula (V) where  $\text{R}^4$  and  $\text{R}^6$  are as defined above and X is a leaving group such as chloro or bromo by reaction with a sulphonyl chloride of formula (VI) where  $\text{Ar}^1$  is as defined in formula (I). The reaction may be carried out in a solvent such as dimethoxyethane, tetrahydrofuran or *N*-methylpyrrolidinone in the presence of a base such as sodium hydride or potassium *tert*-butoxide at room temperature.



(V)

(VI)


Compounds of formula (IV) may be prepared from compounds of formula (VII) where R<sup>6</sup>, X and L are as defined above by reaction with a sulphonyl chloride of formula (VI). The reaction may be carried out in a solvent such as dimethoxyethane, tetrahydrofuran or *N*-methylpyrrolidinone in the presence of a base such as sodium hydride or potassium *tert*-butoxide at room temperature.



(VII)


Compounds of formula (V) where R<sup>4</sup> and R<sup>6</sup> are as defined in formula (I) and X is a leaving group such as chloro or bromo may be prepared from compounds of formula (VII) where R<sup>6</sup> and X are as defined above and L is a leaving group such as chloro or bromo by reaction with a compound R<sup>4</sup>-H in the presence of a suitable base. The compound R<sup>4</sup>-H may be used as the solvent, such as methanol, in which case a suitable base would be sodium methoxide, and the reaction may be performed at a temperature between 20°C and 100°C.

Compounds of formula (VII) where R<sup>6</sup> is as defined in formula (I) and X and L are leaving groups such as bromo may be prepared from the reaction of compounds of the formula (VIII) where R<sup>6</sup> is as defined above with a brominating agent such as bromine or *N*-bromosuccinimide. The reaction may be performed in a solvent such as chloroform at room temperature or reflux in the presence of a base such as pyridine.




(VIII)

Compounds of formula (VIII) are either commercially available or if R<sup>6</sup> is methyl may be prepared from compounds of formula (IX) where L is a leaving group such as chloro by reaction with dimethylzinc in the presence of *bis*(diphenylphosphino)propane]nickel(II) chloride in a solvent such as dioxan at reflux.




Compounds of formula (VI) and (IX) are commercially available.

In addition, in the case where compound (I) has the formula




, wherein  $Ar^1$ ,  $R^4$ ,  $R^6$  and  $R^{11}$  are as defined above, there is provided a process for its preparation which comprises reacting a compound of formula (X),




wherein  $Ar^1$ ,  $R^4$ ,  $R^6$  and  $R^{11}$  are as defined above, with a suitable reducing agent such as triphenylphosphine in the presence of water. The reaction may conveniently be performed in a solvent, for example tetrahydrofuran, at room temperature.

Compounds of formula (X) where  $Ar^1$ ,  $R^4$ ,  $R^6$  and  $R^{11}$  are as defined above may be prepared from compounds of formula (XI) where  $Ar^1$ ,  $R^4$ ,  $R^6$  and  $R^{11}$  are as defined above and P is a suitable protecting group such as trimethylsilylethoxymethyl (SEM) by treatment with a suitable acid such as trifluoroacetic acid in a solvent such as dichloromethane. The reaction may be performed at room temperature.



Compounds of formula (XI) where  $Ar^1$ ,  $R^4$ ,  $R^6$ ,  $R^{11}$  and P are as defined above may be prepared from compounds of formula (XII) where  $Ar^1$ ,  $R^4$ ,  $R^6$ ,  $R^{11}$  and P are as defined above and X is a suitable leaving group such as chloro by treatment with a suitable metal azide such as sodium azide. The reaction may be performed in a solvent such as dimethylformamide at a temperature between 20°C and 100°C.



10


Compounds of formula (XII) where  $Ar^1$ ,  $R^4$ ,  $R^6$ ,  $R^{11}$  and P are as defined above and X is chloro may be prepared from compounds of formula (XII) where  $Ar^1$ ,  $R^4$ ,  $R^6$ ,  $R^{11}$  and P are as defined above and X is hydroxy by treatment with a suitable chlorinating agent such as methanesulphonyl chloride in the presence of a base such as triethylamine. The reaction may be carried out in a solvent such as dichloromethane at room temperature.

15

Compounds of formula (XII) where where  $Ar^1$ ,  $R^4$ ,  $R^6$ ,  $R^{11}$  and P are as defined above and X is hydroxy may be prepared by either:-

20



(a) treatment of compounds of formula (XIII):



where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above with an aldehyde R<sup>11</sup>CHO in the presence of a fluoride source such as tetrabutylammonium fluoride. The reaction may be performed in a solvent such as tetrahydrofuran at room temperature.

Compounds of formula (XIII) where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above may be prepared from compounds of formula (II) where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above by treatment with trimethylsilylmethanethiol in the presence of a base such as cesium carbonate. The reaction may be performed in a solvent such as acetonitrile at room temperature.


(b) treatment of compounds of formula (XIV):



where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above with an epoxide of formula (XV) in the presence of a base such as potassium *tert*-butoxide. The reaction may be performed in a solvent such as tetrahydrofuran at room temperature.


Compounds of formula (XIV) where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above may be prepared from compounds of formula (II) where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above by treatment with 4-pyridineethanethiol in the presence of a base such as cesium carbonate. The reaction may be performed in a solvent such as acetonitrile at room temperature.

(c) treatment of compounds of formula (XVI):



where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above with a reducing agent such as sodium borohydride. The reaction may be performed in a solvent such as ethanol at room temperature.

Compounds of formula (XVI) where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup>, R<sup>11</sup> and P are as defined above may be prepared from compounds of formula (XIV) where Ar<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup> and P are as defined above by treatment with an alkylating agent of formula (XVII) where R<sup>11</sup> is as defined above and X is a leaving group such as chloro or bromo. The reaction may be performed in a solvent such as tetrahydrofuran at room temperature in the presence of a base such as potassium *tert*-butoxide.



It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compound may need to be protected by protecting groups. Thus, the preparation of the compound of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an

acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR4) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:

- (1) **(the respiratory tract)** obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** gout, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** pruritis, scleroderma, otitis, psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis, lupus;
- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, ileitis and enteritis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- (5) **(central and peripheral nervous system)** Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's

disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-Eaton syndrome; spinal disorders, e.g. tropical spastic paraparesis, and stiff-man syndrome; paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; stroke and correctum diseases such as meningitis

- (6) **(other tissues and systemic disease)** hepatitis, vasculitis, spondyloarthropathies, vaginitis, glomerulonephritis, myositis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia pupura; post-operative adhesions, and sepsis.
- (7) **(allograft and xenograft rejection)** acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- (8) Cancer, carcinoma & tumour metastasis, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma. Hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia, B cell lymphoma and Burkett's lymphoma, Hodgkins Lymphoma, Acute Lymphoblastic Leukemia. Hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia. Tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma, and other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.
- (9) All diseases that result from a general imbalance of the immune system and resulting in increased atopic inflammatory reactions.
- (10) Cystic fibrosis, re-perfusion injury in the heart, brain, peripheral limbs and other organs.



(11) Burn wounds & chronic skin ulcers

(12) Reproductive Diseases (e.g. Disorders of ovulation, menstruation and  
implantation, Pre-term labour, Endometriosis)

(13) thrombosis

(14) infectious diseases such as HIV infection and other viral infections, bacterial  
infections.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

Preferably the compound of the invention are used to treat diseases in which the chemokine receptor belongs to the CC chemokine receptor subfamily, more preferably the target chemokine receptor is the CCR4 receptor.

Particular conditions which can be treated with the compound of the invention are asthma, rhinitis and inflammatory skin disorders, diseases in which there are raised TARC, MDC or CCR4 levels. It is preferred that the compound of the invention is used to treat asthma and rhinitis, especially asthma.

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity, particularly CCR4 activity, is beneficial.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CCR4) receptor, which comprises

administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

5 The invention also provides a method of treating a respiratory disease, such as asthma and rhinitis, especially asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

10 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

15 The compound of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, 20 still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

25 The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

30 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.

35 The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compound of the invention is administered orally.

The invention further relates to combination therapies for the treatment of any one of rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, inflammatory bowel diseases, COPD asthma, allergic rhinitis, atopic dermatitis or cancer or the neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease or stroke.

5

For the treatment of rheumatoid arthritis, the compounds of the invention may be combined with "biological agents" such as TNF- $\alpha$  inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and Humira) and soluble TNF receptor immunoglobulin molecules (such as Enbrel.reg.). IL-1 receptor antagonist (such as

10 Anakinra) and IL-1 trap, IL-18 receptor, anti-IL-6 Ab, anti-CD20 Ab, anti-IL-15 Ab and CTLA4Ig.

15

Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin. The cyclooxygenase-2 (COX-2) inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib) and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) and the "disease modifying agents" (DMARDs) such as

20 methotrexate, sulphasalazine, cyclosporine A, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold.

25

The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist selected from the group consisting of zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2n cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline

30 compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

35

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonists for leukotrienes LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub> selected from the group consisting of the phenothiazin-3-ones such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast

(CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the invention together with a phosphodiesterase-4 (PDE4) inhibitor including inhibitors of the isoform PDE4D.

The present invention still further relates to the combination of a compound of the invention together with histaminic H<sub>1</sub> receptor antagonists including cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine.

The present invention still further relates to the combination of a compound of the invention together with a gastroprotective histaminic H<sub>2</sub> receptor antagonist or the proton pump inhibitors (such as omeprazole)

The present invention still further relates to the combination of a compound of the invention together with an  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonist vasoconstrictor sympathomimetic agent, including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.

The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine.

The present invention still further relates to the combination of a compound of the invention together with a  $\beta_1$ - to  $\beta_4$ -adrenoceptor agonists including metaproterenol isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M1, M2, and M3) antagonist.

The present invention still further relates to the combination of a compound of the invention together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX<sub>3</sub>CR1 for the C-X<sub>3</sub>-C family.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

5 The present invention still further relates to the combination of compound of the invention together with an inhaled glucocorticoid with reduced systemic side effects, including prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

10 The present invention still further relates to the combination of a compound of the invention together with (a) tryptase inhibitors; (b) platelet activating factor (PAF) antagonists; (c) interleukin converting enzyme (ICE) inhibitors; (d) IMPDH inhibitors; (e) adhesion molecule inhibitors including VLA-4 antagonists; (f) cathepsins; (g) MAP kinase inhibitors; (h) glucose-6 phosphate dehydrogenase inhibitors; (i) kinin-B<sub>1</sub> - and B<sub>2</sub> - receptor antagonists; (j) anti-gout agents, e.g., colchicine; (k) xanthine oxidase inhibitors, 15 e.g., allopurinol; (l) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (m) growth hormone secretagogues; (n) transforming growth factor (TGF $\beta$ ); (o) platelet-derived growth factor (PDGF); (p) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (q) granulocyte macrophage colony stimulating factor (GM-CSF); (r) capsaicin cream; (s) Tachykinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonists selected 20 from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; and (t) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892 (u) induced nitric oxide synthase inhibitors (iNOS) or (v) chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists).

25 The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), stromelysin-3 (MMP-11), and MMP12 inhibitors.

30 The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, 35 ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, induced nitric oxide synthase inhibitors (iNOS inhibitors), COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) analgesics (such as paracetamol and tramadol), cartilage sparing agents

such as diacerein, doxycycline and glucosamine, and intra-articular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc and P2X7 antagonists.

5 The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of inflammatory bowel diseases (Ulcerative colitis and Crohn's disease). Suitable agents to be used include sulphasalazine, 5-amino-salicylates, the thiopurines, azathioprine and 6-mecaptopurine and corticosteroids such as budesonide.

10 The compounds of the invention may also be used in combination with antiviral agents such as Viracept, AZT, aciclovir and famciclovir, and antiseptis compounds such as Valant.

15 The compounds of the present invention may also be used in combination with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, Angiotensin-2 receptor antagonists and platelet aggregation inhibitors.

20 The compounds of the present invention may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.

25 The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate.

30 The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of cancer. Suitable agents to be used in combination include:

(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel (Taxol®); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-

C, dactinomycin and mithramycin); antimetabolic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

5 (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuporelin and buserelin), progestogens (for example megestrol acetate), aromatase  
10 inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 $\alpha$ -reductase such as finasteride;

(iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);

15 (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [Herceptin<sup>TM</sup>] and the anti-erbB1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family  
20 tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors  
25 of the hepatocyte growth factor family;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin<sup>TM</sup>], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and  
30 compounds that work by other mechanisms (for example linomide, inhibitors of integrin  $\alpha v \beta 3$  function and angiostatin);

(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO99/02166, WO00/40529, WO00/41669, WO01/92224, WO02/04434 and WO02/08213;

35 (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or



a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

- (ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
- 10 The following examples illustrate the invention. The title and sub-title compounds of the examples and methods were named using the Index naming programme version 4.53/07 April 200 from Advanced Chemistry Development Inc.



**Example 1****S-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester**

5

**a) 2,3-Dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide**

- 10 Sodium hydride (1.45g of 60%) was added to 3,5-dichloro-2-pyrazinamine (2.0g) in 1,2-dimethoxyethane (25mL) under nitrogen at room temperature. After 1 hour at room temperature, 2,3-dichlorobenzenesulphonyl chloride (2.94g) was added. After stirring for 30 minutes, 5% aqueous citric acid was added and the product extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO<sub>4</sub>) and the solvent was evaporated. Chromatography on silica eluting with dichloromethane/methanol mixtures gave the subtitled compound as a white solid (3.0g).


15 m/e 372 (M-1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (D6 DMSO) δ 8.29 (1H, s), 8.06 (1H, dd), 7.94 (1H, dd), 7.57 (1H, t)

MP 181-182°C

20

**b) 2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)benzenesulfonamide**




A solution of 2,3-dichloro-*N*-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (20.0g) and sodium methoxide (7.0g) in methanol (300mL) was heated at reflux for 24 hours. The solvent was evaporated and the residue redissolved in water (500mL). The mixture was acidified to pH~1 with concentrated hydrochloric acid giving a white precipitate which was isolated by filtration and dried to afford the subtitled compound as a white solid (19.0g).

$m/e$  368 ( $M-1^-$ , 100%)

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.27 (1H, d), 7.84 (1H, br s), 7.70 (1H, d), 7.62 (1H, s), 7.41 (1H, t), 4.06 (3H, s).

c) 2,3-Dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




To a stirred solution of 2,3-dichloro-*N*-(5-chloro-3-methoxypyrazinyl)benzenesulfonamide (2.2g) and diisopropylethylamine (1.3mL) in dichloromethane (100mL) was added 2-(trimethylsilyl)ethoxymethyl chloride (1.3mL). After stirring for 30min at room temperature, the reaction mixture was washed with water and brine, and the organic phase dried over magnesium sulphate, filtered and evaporated to give a white solid. This was purified by silica gel chromatography, eluting with 10:1 isohexane:ethyl acetate, to afford the subtitled compound as a white solid (2.8g).

$m/e$  498 ( $M+1^+$ , 100%)

$^1H$  NMR ( $CDCl_3$ )  $\delta$  8.00 (1H, s), 7.97 (1H, dd), 7.67 (1H, dd), 7.29 (1H, t), 5.24 (2H, s), 3.91 (3H, s), 3.79-3.73 (2H, m), 0.87-0.82 (2H, m), 0.00 (9H, s).


d) *S*-[5-[[2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy)methyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester



To a stirred solution of 2,3-Dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy)methyl]benzenesulfonamide (0.15g) and D-cysteine methyl ester hydrochloride (0.1g) in acetonitrile (5mL) was added caesium carbonate (0.39g) and the reaction mixture stirred at room temperature under an atmosphere of nitrogen for 18 hours. After evaporation of solvent the residue was partitioned between brine and dichloromethane, and the organic phase dried over magnesium sulphate, filtered and evaporated. The crude product was purified by silica gel chromatography, eluting with 2:1 dichloromethane:ethyl acetate, to afford the subtitled compound as a colourless oil (0.09g). *m/e* 597 (*M*+1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.97 (1H, d), 7.89 (1H, s), 7.65 (1H, d), 7.27 (1H, t), 5.23 (2H, s), 3.91 (3H, s), 3.81-3.68 (3H, m), 3.72 (3H, s), 3.26-3.19 (2H, m), 0.89-0.83 (2H, m), 0.00 (9H, s).

e) *S*-[5-[[2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester



A solution of *S*-[5-[[2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy)methyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester (0.08g) in a mixture of dichloromethane (5mL) and trifluoroacetic acid (3mL) was stirred at room temperature for 1 hour. After evaporation of solvent the residue was purified by

silica gel chromatography, eluting with 10:1 dichloromethane:methanol, to afford the title product as a white solid (0.05g).


m/e 465 (M-1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.05 (1H, d), 7.94 (1H, d), 7.69 (1H, s), 7.58 (1H, t), 4.36 (1H, t), 3.95 (3H, s), 3.71 (1H, dd), 3.60 (3H, s), 3.46 (1H, dd).

## Example 2


### S-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester

a) S-[5-[[[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester



To a solution of 2,3-dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (0.300g) and N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.13mL) in acetonitrile (10mL) was added caesium carbonate (0.200g) and the mixture stirred under nitrogen at room temperature for 24 hours. The mixture was added to water and the product extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO<sub>4</sub>) and the solvent was evaporated to give the subtitled compound as an oil (0.42g). m/e 697 (M-1<sup>+</sup>, 100%)

b) S-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl



ester

Procedure as for Example 1 step e) using S-[5-[[[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.300g). Yield 0.075g.


5 m/e 467 ( $M+1^+$ , 100%)

$^1\text{H}$  NMR (DMSO)  $\delta$  8.17 (2H, bs), 7.96 (1H, dd), 7.68 (1H, dd), 7.40 (1H, t), 7.34 (1H, s), 4.20 (1H, t), 3.83 (3H, s), 3.52 (3H, s), 3.40 (2H, m).

MP 170-4°C

10 **Example 3**

**S-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine**



To a stirred solution of S-[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester (0.100g) in tetrahydrofuran (20mL) was added a solution of lithium hydroxide (0.090g) in water (5mL). After stirring at room temperature for 4 hours, the reaction mixture was poured into 2M hydrochloric acid and extracted with dichloromethane (x3). The aqueous extract was evaporated to approximately 5mL. The title compound crystallised as a white solid (0.050g).

20 m/e 453 ( $M+1^+$ , 100%)


$^1\text{H}$  NMR (DMSO)  $\delta$  8.51 (3H, bs), 8.05 (1H, d), 7.95 (1H, d), 7.71 (1H, s), 7.59 (1H, t), 4.21 (1H, m), 3.96 (3H, s), 3.75 (1H, dd), 3.51 (1H, dd).

MP 180-90°C

25 **Example 4**

**(2R)-2-Amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide**


a) S-[5-[[[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine



To a stirred solution of S-[5-[[[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.500g) in tetrahydrofuran (20mL) was added a solution of lithium hydroxide (0.300g) in water (5mL). After stirring at room temperature for 2 days, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x2). The combined extracts were washed with saturated brine, dried (MgSO<sub>4</sub>) and the solvent was evaporated. The residue was purified by silica gel chromatography, eluting with 3:1 ethyl acetate:methanol, to afford the subtitled product as a solid (0.200g).  
m/e 681 (M-1<sup>-</sup>, 100%)

b) [(1R)-2-Amino-1-[[[5-[[[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester.


A solution of S-[5-[[[(2,3-dichlorophenyl)sulfonyl][[2-



(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine (0.500g) in tetrahydrofuran (10mL) was cooled to 0°C under nitrogen and isobutyl chloroformate (0.105mL) was added dropwise. After 30

minutes at 0°C 0.88 ammonia solution was added and allowed to warm to room temperature. After stirring at room temperature for 24 hours, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO<sub>4</sub>) and the solvent was evaporated to afford the subtitled product as an oil (0.550g).  
 m/e 682 (M-1<sup>-</sup>, 100%).

c) (2*R*)-2-Amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide



Procedure as for Example 1 step e) using [(1*R*)-2-amino-1-[[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.250g) Yield 0.150g.

m/e 452 (M+1<sup>+</sup>, 100%)


<sup>1</sup>H NMR (DMSO) δ 7.95 (1H, d), 7.77 (1H, s), 7.61 (1H, d), 7.48 (1H, s), 7.36 (2H, bs), 7.35 (1H, t), 7.33 (1H, s), 3.74 (1H, m), 3.28 (1H, m), 3.08 (1H, m).

MP 148-52°C

## Example 5

(2*R*)-2-Amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-N-methyl-propanamide

a) [(1*R*)-1-[[[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester




6-methoxypyrazinyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester.

Procedure as for Example 4 step b) using methylamine. Yield 0.230g.

m/e 696 ( $M+1^+$ , 100%)

5

b) (2*R*)-2-Amino-3-[[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide,



Procedure as for Example 1 step e) using [(1*R*)-1-[[[5-[[2,3-dichlorophenyl)sulfonyl]amino]-2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.200g).

10

Yield 0.060g.

m/e 464 ( $M-1^-$ , 100%)

$^1\text{H}$  NMR (DMSO)  $\delta$  8.30 (1H, m), 8.05 (2h, bs), 7.96 (1H, dd), 7.63 (1H, dd), 7.36 (1H, t), 7.31 (1H, s), 3.80 (4H, m), 3.32 (3H, s), 3.25 (1H, m), 3.14 (1H, m).

15


MP 160-4°C

### Example 6

(2*R*)-2-Amino-3-[[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N,N*-dimethylpropanamide

20

a) [(1*R*)-1-[[[5-[[2,3-Dichlorophenyl)sulfonyl]amino]-2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-(dimethylamino)-2-oxoethyl]carbamic acid 1,1-






dimethylethyl ester.

Procedure as for Example 4 step b) using dimethylamine. Yield 0.220g.

m/e 710 (M-1<sup>+</sup>, 100%)

- 5 b) (2*R*)-2-Amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N,N*-dimethylpropanamide



Procedure as for Example 1 step e) using [(1*R*)-1-[[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-

- 10 (dimethylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.200g).

Yield 0.055g.

m/e 480 (M+1<sup>+</sup>, 100%)


<sup>1</sup>H NMR (DMSO) δ 8.05 (2h, bs), 7.95 (1H, d), 7.62 (1H, d), 7.35 (1H, t), 7.28 (1H, s), 4.43 (1H, t), 3.81 (3H, s), 3.26 (1H, m), 3.15 (1H, m), 2.89 (3H, s), 2.66 (3H, s).

- 15 MP 187-90°C

### Example 7


- 20 *N*-[5-[[[(2*R*)-2-Amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

a) [(1*R*)-2-[[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester



To a stirred solution of S-[5-[[[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.120g) in tetrahydrofuran (10mL) under nitrogen was added a 1.0M solution of lithium triethylborohydride in tetrahydrofuran (0.7mL). After stirring at room temperature for 1 day, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO<sub>4</sub>) and the solvent evaporated. The residue was purified by silica gel chromatography, eluting with 2:3 ethyl acetate:isohexane, to afford the subtitled product as an oil (0.075g).  
 m/e 669 (M+1<sup>+</sup>, 100%)

b) N-[5-[[[(2R)-2-Amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide




Procedure as for Example 1 step e) using [(1R)-2-[[[5-[[[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester (0.075g).  
 Yield 0.024g.  
 m/e 437 (M-1<sup>-</sup>, 100%)

$^1\text{H}$  NMR (DMSO)  $\delta$  8.05-7.93 (4H, m), 7.71 (1H, s), 7.58 (1H, t), 5.38 (1H, m), 3.94 (3H, s), 3.66-3.23 (5H, m).

### Example 8

#### *S*-[3-Chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester


##### a) 3-Methoxy-5-bromo-6-chloro-2-pyrazinamine



A stirred solution of 2-amino-6-chloropyrazine (2.0g) and *N*-bromosuccinimide (13.71g) in chloroform (100 mL) was heated to reflux for 20 hours. The reaction mixture was cooled and concentrated onto silica gel (20g) and the residue loaded onto a column of silica gel (5cm x 2cm) and the column was eluted with dichloromethane. Concentration afforded 3,5-dibromo-6-chloro-2-aminopyrazine that was dissolved into methanol (200 mL) and sodium methoxide (32g of a 25% solution in methanol) added. The reaction was heated to 70°C for 1.5h, cooled and concentrated to approx. 50 mL capacity. The reaction mixture was poured into water (200mL) and the sub-titled adduct (2.0g) collected as an off-white solid.

$m/e$  235, 237 ( $M+1^+$ , 100%)

##### b) *N*-(5-Bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichlorobenzenesulphonamide




Procedure as for Example 1 step a), (reaction performed at room temperature) using 3-methoxy-5-bromo-6-chloro-2-pyrazinamine (Example 125a) (0.5g) and 2,3-dichlorobenzenesulphonyl chloride (2.21g). Yield 3.2g.

$m/e$  445, 447 ( $M-1^+$ , 100%)

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.32 (1H, dd), 7.79 (1H, br), 7.72 (1H, dd), 7.45 (1H, t), 4.05 (3H, s).

MP 177-178°C

c) *N*-(5-bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 1 step c) using *N*-(5-Bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichlorobenzenesulphonamide (1.75g). Yield 2.20g.

5 m/e 447 (M+1-SEM<sup>+</sup>, 100%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.02 (1H, d), 7.71 (1H, d), 7.35 (1H, t), 5.23 (2H, s), 3.96 (3H, s), 3.72 (2H, t), 0.84 (2H, t), 0.00 (9H, s).


d) *S*-[3-Chloro-5-[[[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester



Procedure as for Example 2 step a) using *N*-(5-bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (0.400g). Yield 0.480g. m/e 631 ([M-Boc]+1<sup>+</sup>, 100%)

15

e) *S*-[3-Chloro-5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine,



methyl ester

Procedure as for Example 1 step e) using *S*-[3-chloro-5-[[2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.300g). Yield 0.120g.

*m/e* 503 ( $M+1^+$ , 100%)


$^1\text{H}$  NMR (DMSO)  $\delta$  8.40 (2H, bs), 8.02 (1H, d), 7.65 (1H, d), 7.39 (1H, t), 4.30 (1H, m), 3.86 (3H, s), 3.66 (1H, m), 3.61 (3H, s), 3.34 (1H, m).

MP 170-3°C

### Example 9

***S*-[3-Chloro-5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine**

Procedure as for Example 3 using *S*-[3-chloro-5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-



methoxypyrazinyl]-L-cysteine, methyl ester (0.070g). Yield 0.050g

*m/e* 488 ( $M+1^+$ , 100%)


$^1\text{H}$  NMR (DMSO)  $\delta$  8.51 (3H, bs), 8.03 (1H, dd), 7.70 (1H, d), 7.42 (1H, t), 4.16 (1H, m), 3.87 (3H, s), 3.74 (1H, dd), 3.30 (1H, m).

MP 170-3°C

### Example 10

***N*-[5-[[2,3-dichlorophenyl)sulfonyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide**


a) [(1*R*)-2-[[3-Chloro-5-[[2,3-dichlorophenyl)sulfonyl][[2-



(trimethylsilyl)ethoxy)methyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester

Procedure as for Example 7 step a) using *S*-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl][2-(trimethylsilyl)ethoxy)methyl]amino]-6-methoxypyrazinyl]-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.175g). Yield 0.170g  
 m/e 603 (M+1-BOC<sup>+</sup>, 100%)

b) *N*-[5-[(2*R*)-2-Amino-3-hydroxypropyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



Procedure as for Example 1 step e) using [(1*R*)-2-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl][2-(trimethylsilyl)ethoxy)methyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester (0.170g).

Yield 0.032g.

m/e 475 (M+1<sup>+</sup>, 100%)


<sup>1</sup>H NMR (DMSO) δ 8.01 (1H, dd), 7.91 (3H, bs), 7.63 (1H, t), 5.32 (1H, m), 3.82 (3H, s), 3.65 (1H, m), 3.57 (1H, m), 3.25-3.12 (2H, m).

MP 255-6°C

## Example 11


***S*-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, methyl ester**

a) 6-Methyl-2-pyrazinamine




Dimethylzinc (100mL of a 2M solution in toluene) was added dropwise over 0.5h to a stirred solution of 6-chloro-2-pyrazinamine (12.9g) and [1,3-bis(diphenylphosphino)propane]nickel(II) chloride (5.4g) in dioxane (200mL) under a nitrogen atmosphere. The reaction mixture was heated at reflux for 18h, then cooled to room temperature and quenched cautiously with *iso*-propanol (30mL) and methanol (50mL). After removal of solvent *in vacuo*, the residue was partitioned between dichloromethane and aqueous ammonium chloride. The organic phase was filtered through celite, dried (MgSO<sub>4</sub>), filtered and evaporated to give the crude product as an orange solid. Chromatography on silica gel eluting with ethyl acetate/methanol mixtures gave the subtitle compound (5.1g). Used directly.

b) 3,5-Dibromo-6-methyl-2-pyrazinamine



A solution of bromine (1.85g) in chloroform (5mL) was added dropwise to a stirred solution of 2-amino-6-methylpyrazine (0.6g) and pyridine (0.9 ml) in chloroform (50mL). The reaction mixture was stirred at room temperature for 0.5h, then washed twice with water, dried (MgSO<sub>4</sub>), filtered and evaporated to give the crude product as an orange solid. Chromatography on silica gel eluting with dichloromethane gave the title compound (0.95g). Used directly.


c) 5-Bromo-3-methoxy-6-methyl-2-pyrazinamine



3,5-Dibromo-6-methyl-2-pyrazinamine (0.9g) was added to a solution of sodium (0.39g) in methanol (30mL) and the mixture heated at reflux for 18h. After removal of solvent *in vacuo*, the residue was partitioned between water and dichloromethane, and the organic phase dried (MgSO<sub>4</sub>), filtered and evaporated to give the title compound as a pale yellow solid (0.58g).

*m/e* 218/220 (M+1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.70 (2H, br s), 3.97 (3H, s), 2.40 (3H, s)


d) *N*-[5-Bromo-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulphonamide

Sodium hydride (0.5g of a 60% dispersion in oil) was added to a solution of 5-bromo-3-methoxy-6-methyl-2-pyrazinamine (0.55g) in *N*-methylpyrrolidinone (25mL). The resultant dark solution was stirred at room temperature for 0.5h before a solution of 2,3-dichlorobenzenesulphonyl chloride (0.67g) in *N*-methylpyrrolidinone (5mL) was added dropwise. The reaction mixture was stirred at room temperature for 3h, then quenched with aqueous ammonium chloride and partitioned between ethyl acetate and aqueous ammonium chloride (x5). The organic phase was dried (MgSO<sub>4</sub>), filtered and evaporated to give the crude product. Chromatography on silica gel eluting with dichloromethane/ acetic acid (200:1) gave the sub-title compound as a pale yellow solid (0.38g).

*m/e* 424/426/428 (M-1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.29 (1H, d), 7.69 (2H, d), 7.41 (1H, t), 4.01 (3H, s), 2.27 (3H, s)

MP 146-148°C

e) *N*-(5-Bromo-3-methoxy-6-methylpyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide


Procedure as for Example 1 step c) using *N*-[5-bromo-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulphonamide (7.0g).

Yield 6.7g

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01 (1H, d), 7.68 (1H, d), 7.30 (1H, t), 5.24 (2H, s), 3.89 (3H, s), 3.74 (2H, m), 2.47 (3H, s), 0.84 (2H, m), 0.00 (9H, s).



f) *S*-[5-[[[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxy-3-methylpyrazinyl]-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester




- 5 Procedure as for Example 2 step a) using the product of Example 13 step e) (0.1g) and *N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.05g).

Yield 0.045g.

- <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01 (1H, d), 7.66 (1H, d), 7.28 (1H, t), 5.40 (1H, m), 5.21 (2H, AB), 4.65 (1H, m), 3.91 (3H, s), 3.77 (2H, m), 3.70 (3H, s), 3.52 (1H, m), 2.29 (3H, s), 1.43 (9H, s), 0.85 (2H, m), 0.01 (9H, s).

g) *S*-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, methyl ester



- 15 Procedure as for Example 1 step e) using *S*-[5-[[[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxy-3-methylpyrazinyl]-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.045g).

Yield 0.018g.


*m/e* 481 (*M*+1<sup>+</sup>, 100%)

- <sup>1</sup>H NMR (D<sub>6</sub>-DMSO) δ 8.07 (1H, d), 7.70 (1H, d), 7.43 (1H, t), 4.06 (1H, t), 3.81 (3H, s), 3.51 (3H, s), 3.53-3.49 (1H, m), 3.34-3.29 (1H, m), 1.92 (3H, s).

MP 164-168°C

**Example 12**

***S*-[5-[[2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, oxalate salt**



A solution of *S*-[5-[[2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, methyl ester (0.065g) and lithium hydroxide (0.011g) in tetrahydrofuran (2mL) and water (2mL) was heated at reflux for 4h. After removal of solvent *in vacuo*, the crude product was purified by reverse phase preparative hplc, followed by treatment with one equivalent of oxalic acid, to give the title compound as a pale brown solid.

Yield 0.021g.


m/e 467 (M+1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (D6-DMSO) δ 8.07 (1H, d), 7.66 (1H, d), 7.41 (1H, t), 3.82 (3H, s), 3.73 (1H, dd), 3.51 (1H, d), 3.02 (1H, m), 1.92 (3H, s).

**Example 13**

***N*-(2-Aminoethyl)-*S*-[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, ethyl ester**

a) *S*-[5-[[2,3-Dichlorophenyl)sulfonyl][2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-L-cysteine, ethyl ester




Procedure as for Example 1 step d) using 2,3-dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (1.0g) and L-cysteine ethyl ester hydrochloride (0.45g).

5 Yield 0.9g.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.97 (1H, d), 7.89 (1H, s), 7.65 (1H, d), 7.27 (1H, t), 5.23 (2H, s), 4.18 (2H, q), 3.91 (3H, s), 3.80-3.71 (4H, m), 3.21-3.16 (1H, m), 1.26 (3H, t), 0.86 (2H, m), 0.01 (9H, s).

10 b) *N*-(2-Aminoethyl)-*S*-[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, ethyl ester



A solution of *S*-[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, ethyl ester (0.35g), *tert*-butyl *N*-(2-oxoethyl)carbamate (0.27g) and sodium triacetoxyborohydride (0.36g) in acetonitrile (7mL) was stirred at room temperature for 30min before removal of solvent *in vacuo*. The residue was dissolved in a mixture of dichloromethane (5mL) and trifluoroacetic acid (2mL) and stirred at room temperature for 1h. After removal of solvent *in vacuo*, the crude product was purified by silica gel chromatography, eluting with 10:1 dichloromethane:methanol, to afford the title product as a pale brown solid.

Yield 0.27g

m/e 522 (M-1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.21 (1H, d), 7.67 (1H, d), 7.56 (1H, br s), 7.40 (1H, t), 4.12 (2H, q), 4.03 (3H, s), 3.85 (1H, m), 3.69 (1H, m), 3.35 (1H, m), 3.25 (4H, br s), 1.20 (3H, t).


5

#### Example 14

#### *N*-[5-[[*(2R)*-2-Amino-2-phenylethyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

10

a) *N*-[5-[[*(2R)*-2-Amino-2-phenylethyl]oxy]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide



15 2,3-Dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g) and *R*-(-)-2-phenylglycinol (0.075g) were dissolved in dry DMF (10 ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.035g). After stirring at ambient temperature for 20 hr the reaction was poured into brine and extracted with ethyl acetate (3 x 50 ml). The organic extracts were washed with brine, dried (MgSO<sub>4</sub>) and evaporated to give the sub-title product as an oil.


20

Yield 0.2g.

m/e 599 (M<sup>+</sup>, 100%)

b) *N*-[5-[[*(2R)*-2-Amino-2-phenylethyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

25



The product from Example 14 step a) (0.2 g) was subjected to the procedure described for Example 1 step e) to afford the title product which crystallised from diethyl ether/hexane. Yield 0.032g


5 MP 138-140 °C

m/e 467 (M-1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.92 (1H, dd), 7.64 (1H, dd), 7.32-7.53 (6H, m), 7.08 (1H, s), 4.63 (1H, m), 4.25-4.40 (2H, m), 3.76 (3H, s).


#### 10 Example 15

**2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide**



15


a) 2,3-Dichloro-N-[3-methoxy-5-[[2-(4-pyridinyl)ethyl]thio]pyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide



2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (10 g) and 4-pyridineethanthiol hydrochloride (4 g) were dissolved in acetonitrile (200 ml), treated with caesium carbonate (16 g) and stirred at ambient temperature for 24 hr. The mixture was partitioned between ethyl acetate (200 ml) and 2M HCl (200 ml). The ethyl acetate extract was washed with 2 M HCl (100 ml), water (100 ml), brine (100 ml), dried (MgSO<sub>4</sub>) and evaporated to give the sub-title compound as a solid (9.1 g).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.55 (2H, d), 7.99 (1H, m), 7.87 (1H, s), 7.67 (1H, m), 7.28 (1H, m), 7.15 (2H, d), 5.23 (2H, s), 3.90 (3H, s), 3.79 (2H, t), 3.40 (2H, t), 3.03 (2H, t), 0.87 (2H, t), 0.00 (9H, s).

b) 2-[[5-[[2,3-Dichlorophenyl)sulfonyl]][2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-N-methoxy-N-methyl-acetamide.




The product from Example 15 step a) (4 g) was dissolved in dry THF (25 ml) under an atmosphere of nitrogen and treated with a 1 M solution of potassium *tert*-butoxide in THF (10 ml), added dropwise. After stirring for 30 min the reaction was treated with a saturated solution of ammonium chloride (20 ml) followed by 2M HCl (100 ml) and extracted into ethyl acetate (200 ml). The ethyl acetate extract was washed with water (2 x 100 ml),

brine (100 ml), dried (MgSO<sub>4</sub>) and evaporated to leave a gum (3.5 g). This was dissolved in dry THF (25 ml) and treated with a 1 M solution of potassium *tert*-butoxide in THF (5 ml) and 2-chloro-*N*-methoxy-*N*-methyl-acetamide (1 g) added as a solution in THF (5 ml). The mixture was stirred at ambient temperature for 1 hr and partitioned between ethyl acetate (200 ml) and 2 M HCl (100 ml). The ethyl acetate extract was washed with water (2 x 100 ml), brine (100 ml), dried (MgSO<sub>4</sub>) and evaporated to give the sub-titled compound as a yellow gum (3.32 g).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.98 (1H, dd), 7.94 (1H, s), 7.66 (1H, dd), 7.24 (1H, m), 5.21 (2H, s), 4.14 (2H, s), 3.87 (3H, s), 3.79 (2H, t), 3.76 (3H, s), 3.22 (3H, s), 0.87 (2H, t), 0.00 (9H, s).

c) 2,3-Dichloro-*N*-[3-methoxy-5-[[2-oxo-2-(2-thiazolyl)ethyl]thio]pyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




Thiazole (0.17 g) was dissolved in dry THF (10 ml), cooled to -30 °C and stirred under an atmosphere of nitrogen. Butyl lithium (1.5 M, 1.5 ml) was added dropwise and the reaction was stirred for 30 mins and became a dark-orange colour. The product of Example 15 step b) (0.3 g) in THF (3 ml) was added dropwise and the reaction mixture was stirred between -20 to -10 °C for 2.5 hrs. The mixture was then poured into 2 M HCl (25 ml) and extracted into ethyl acetate (50 ml). The ethyl acetate extract was washed with water (2 x 20 ml), brine (20 ml), dried (MgSO<sub>4</sub>) and evaporated to give a gum which was purified by silica gel chromatography, using hexane:ethyl acetate (2:1) as eluant to give the sub-titled compound as a yellow gum (0.1 g).

*m/e* 622 (M+1)<sup>+</sup>

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.06 (1H, d), 7.96 (1H, s), 7.88 (1H, dd), 7.76 (1H, d), 7.65 (1H, dd), 7.25 (1H, m), 5.21 (2H, s), 4.75 (2H, s), 3.75 (2H, t), 3.53 (3H, s), 0.85 (2H, t), 0.01 (9H, s).

d) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide




The product of Example 15 step c) was dissolved in acetonitrile (3 ml) and treated with sodium triacetoxyborohydride and stirred at ambient temperature for 48 hr. The reaction mixture was treated with TFA (3 mls) for 30 mins and then partitioned between ethyl acetate (20 ml) and 2 M HCl (10 ml). The ethyl acetate extract was washed with water (2 x 20 ml), brine (20 ml), dried (MgSO<sub>4</sub>) and evaporated to give a gum which was purified by silica gel chromatography, using hexane:ethyl acetate (1:1) as eluant to give the sub-  
titled compound as a yellow solid (0.03 g).

*m/e* 491/493/495 (M-1)<sup>+</sup>

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.28 (1H, d), 7.6-7.7 (2H, m), 7.39 (1H, d), 7.76 (1H, d), 7.28 (1H, m), 4.25 (1H, m), 4.1 (3H, s), 3.99 (1H, d), 3.7-3.75 (1H, m), 3.41-3.49 (1H, m).


### Example 16

2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide, potassium salt





a) 2,3-Dichloro-*N*-[3-methoxy-5-[[2-(trimethylsilyl)ethoxy]methyl]thio]pyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide



5


A solution of 2,3-dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (3.2g), trimethylsilylmethane thiol (1.0ml) and cesium carbonate (4.2g) in acetonitrile (50ml) was stirred under an atmosphere of nitrogen at room temperature for two hours. The reaction mixture was filtered and evaporated, and the residue purified by silica gel chromatography, using isohexane:ethyl acetate (10:1) as eluant, to give the sub-titled compound as a colourless oil (2.8g).

10

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.95 (1H, d), 7.89 (1H, s), 7.64 (1H, d), 7.25 (1H, t), 5.24 (2H, s), 3.86 (3H, s), 3.82-3.76 (2H, m), 2.31 (2H, s), 0.89-0.84 (2H, m), 0.15 (9H, s), 0.01 (9H, s).

15

b) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




20

To a solution of 2,3-dichloro-*N*-[3-methoxy-5-[[2-(trimethylsilyl)ethoxy]methyl]thio]pyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.5g) and 1-methyl-2-imidazolecarboxaldehyde (94mg) in tetrahydrofuran (2ml) was added tetrabutylammonium fluoride (0.1ml of a 1M solution in THF), and the mixture stirred at room temperature

under an atmosphere of nitrogen for 5 minutes. The solvent was removed *in vacuo* and the residue purified by silica gel chromatography, eluting with 1:1 ethyl acetate:dichloromethane and ethyl acetate, to afford the sub-titled product as a colourless oil (0.12g).

5  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.97 (1H, d), 7.88 (1H, s), 7.65 (1H, d), 7.27 (1H, t), 6.96 (1H, s), 6.81 (1H, s), 5.22 (2H, s), 4.98 (1H, t), 3.88 (3H, s), 3.84-3.74 (5H, m), 3.68 (3H, s), 0.88-0.84 (2H, m), 0.00 (9H, s).

10 c) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide, potassium salt




15 A solution of the product from step b) (75mg) in dichloromethane (4ml) and trifluoroacetic acid (2ml) was stirred at room temperature for 30 minutes. The solvent was removed *in vacuo* and the residue purified by reverse phase preparative hplc, followed by treatment with one equivalent of potassium hydroxide, to give the title compound as a white solid. Yield 0.031g.

$m/e$  490/492 ( $M+1$ )<sup>+</sup>

20  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  7.93 (1H, d), 7.60 (1H, d), 7.34 (1H, t), 7.19 (1H, s), 7.01 (1H, s), 6.74 (1H, s), 4.75 (1H, t), 3.79 (3H, s), 3.59 (3H, s), 3.48-3.42 (1H, m), 3.31-3.24 (1H, m).


### Example 17

25 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide



a) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide

5



Using the procedure of Example 16 step (b) 2,3-dichloro-*N*-[3-methoxy-5-[[2-(trimethylsilyl)ethoxy]methyl]thio]pyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.7g) was reacted with oxazole-2-carboxaldehyde (0.14g) in the presence of tetrabutylammonium fluoride (0.6ml of a 1M solution in THF) in tetrahydrofuran (3ml).

10


Yield 0.080g

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.97 (1H, d), 7.91 (1H, s), 7.65 (1H, d), 7.61 (1H, s), 7.28 (1H, t), 7.08 (1H, s), 5.22 (2H, s), 5.14-5.09 (1H, m), 3.91 (3H, s), 3.80-3.64 (3H, m), 3.66-3.59 (1H, m), 3.55 (1H, br d), 0.88-0.83 (2H, m), 0.01 (9H, s).

15

b) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide

20



Using the procedure of Example 16 step (c) the title compound was obtained by treating 2,3-dichloro-*N*-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (80mg) with trifluoroacetic acid (2ml) in dichloromethane (2ml).


Yield 0.056g

*m/e* 475/477 (*M*-1)<sup>+</sup>


<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) 7.97 (1H, s), 7.93 (1H, d), 7.60 (1H, d), 7.34 (1H, t), 7.14 (1H, s), 7.10 (1H, s), 4.75 (1H, t), 3.79 (3H, s), 3.35-3.21 (2H, m).

### Example 18

*N*-[5-[[2-Amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide




a) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide



To a solution of 2,3-dichloro-*N*-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.35g) in dichloromethane (10ml) was added methanesulphonyl chloride (0.45ml) and triethylamine (1.2ml). The reaction was stirred at room temperature for two hours then diluted with ethyl acetate, washed with brine, dried over magnesium sulphate, filtered and evaporated to give the sub-titled compound as a yellow oil (0.41g).

*m/e* 627/629 (M+1)<sup>+</sup>

- b) *N*-[5-[[2-Azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




- A solution of 2,3-dichloro-*N*-[5-[[2-chloro-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.41g) and sodium azide (0.11g) in dimethylformamide (10ml) was heated at 65°C for two hours. The cooled reaction mixture was diluted with diethyl ether and washed once with brine and three times with saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give the sub-titled compound as a yellow oil (0.24g).

m/e 502/504 (M-130+1)<sup>+</sup> (loss of [(trimethylsilyl)ethoxy]methyl)

c) *N*-[5-[[2-Azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

5




A solution of *N*-[5-[[2-azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.24g) in dichloromethane (10ml) and trifluoroacetic acid (3ml) was stirred at room temperature for one hour. The solvent was removed *in vacuo* and the residue purified by silica gel chromatography, eluting with 1:1 ethyl acetate:isohexane/0.5% acetic acid to give the sub-titled compound as a colourless oil (0.16g).

10

m/e 500/502 (M-1)<sup>-</sup>

d) *N*-[5-[[2-Amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

15



A solution of *N*-[5-[[2-azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide (0.16g) and triphenylphosphine (0.16g) in tetrahydrofuran (10ml) and water (2ml) was stirred at room temperature for 20 hours. Methanol (10ml) and 10% aqueous sodium hydroxide (2ml) were added and the reaction mixture stirred at room temperature a further 24 hours. The reaction mixture was concentrated, acidified with 2M aqueous hydrochloric acid and extracted with dichloromethane (5x). The combined organic phases were dried over magnesium sulphate, filtered and evaporated to give a yellow solid which was purified by reverse phase preparative hplc to give the title compound as a white solid.

Yield 0.08g


m.p. 168-170°C

m/e 476/478 (M+1)<sup>+</sup>


<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 8.12 (1H, s), 7.99 (1H, d), 7.68 (1H, d), 7.40 (1H, t), 7.26 (1H, s), 7.24 (1H, s), 4.59 (1H, m), 3.75 (3H, s), 3.57-3.52 (1H, m), 3.45-3.39 (1H, m).


### Example 19

#### 2,3-Dichloro-*N*-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]benzenesulfonamide



a) 2,3-Dichloro-*N*-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.






Procedure as for Example 1 step d) using 3-mercaptopropane-1,2-diol. Yield 0.350g.  
m/e 570 (M+1<sup>+</sup>)

5

b) 2,3-Dichloro-*N*-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]benzenesulfonamide.



10

Procedure as for Example 1 step e) using 2,3-dichloro-*N*-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.

Yield 0.018g.

m/e 440 (M+1<sup>+</sup>, 100%)




$^1\text{H}$  NMR (DMSO)  $\delta$  11.27 (1H, bs), 8.02 (1H, d), 7.93 (1H, d), 7.67 (1H, s), 7.57 (1H, t), 3.89 (3H, s), 3.62 (1H, m), 3.40 (3H, m), 2.98 (1H, m).

MP 136-8°C


5 **Example 20**

**2,3-Dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]benzenesulfonamide**



10

a) 2,3-Dichloro-*N*-[3-methoxy-5-[(2-oxo-2-phenylethyl)thio]pyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.




15

The product from Example 15 step a) (1.0 g) was dissolved in dry THF (20 ml) under an atmosphere of nitrogen and treated with a 1 M solution of potassium *tert*-butoxide in THF (2.5 ml), added dropwise. After stirring for 60 min the reaction was treated with phenacyl bromide (0.37 g) and allowed to stir for 20 hrs. The reaction mixture was poured into saturated aqueous ammonium chloride solution and extracted into ethyl acetate (x3). The combined ethyl acetate extracts were washed with water, brine and dried ( $\text{MgSO}_4$ ) and evaporated to leave an oil. The residue was purified by silica gel chromatography, eluting with 1:4 ethyl acetate:isohexane, to afford the sub-titled product as a colourless oil (0.87g).

m/e 614 (M+1<sup>+</sup>, 100%)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.02 (2H, m), 7.95 (2H, m), 7.63 (2H, m), 7.52 (2H, m), 7.25 (1H, m), 5.20 (2H, s), 4.59 (2H, s), 3.76 (2H, m), 3.56 (3H, s), 0.85 (2H, t), 0.00 (9H, s).

- 5 b) 2,3-Dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.




10 The product from Example 20 step a) (0.33 g) was dissolved in EtOH (5 ml) under an atmosphere of nitrogen and treated with sodium borohydride (0.042 g). The reaction was stirred for 24 hrs then poured into water and extracted into ethyl acetate (x3). The combined ethyl acetate extracts were washed with brine, dried (MgSO<sub>4</sub>) and evaporated to afford the sub-titled product as a colourless oil (0.30g).

m/e 616 (M+1)<sup>+</sup>

15

- c) 2,3-Dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]benzenesulfonamide.



20

Procedure as for Example 1 step e) using the product from Example 20 step b) (0.30 g). Yield 0.022g.


m/e 484 (M-1)<sup>-</sup>

<sup>1</sup>H NMR (DMSO) δ 8.02 (1H, dd), 7.94 (1H, dd), 7.58 (2H, m), 7.35 (2H, d), 7.17-7.29 (3H, m), 5.64 (1H, s), 4.75 (1H, t), 3.89 (3H, s), 3.27-3.46 (2H, m).

MP 141-3°C


5 **Example 21**

**2,3-Dichloro-N-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide**



10

a) 2,3-Dichloro-N-[3-methoxy-5-[[2-oxo-2-(3-pyridinyl)ethyl]thio]pyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide



15


Procedure as for Example 20 step a) using 3-(bromoacetyl)pyridine hydrobromide (0.70 g).

Yield 1.55g

m/e 615 (M+1<sup>+</sup>)

20

b) 2,3-Dichloro-N-[3-methoxy-5-[[2-oxo-2-(3-pyridinyl)ethyl]thio]pyrazinyl]benzenesulfonamide



Procedure as for Example 1 step e) using the product from Example 21 step a) (0.16 g).


Yield 0.122g.

m/e 483 (M-1)<sup>-</sup>

- 5 <sup>1</sup>H NMR (DMSO) δ 11.32 (1H, bs), 9.22 (1H, m), 8.81 (1H, m), 8.37 (1H, m), 8.02 (1H, dd), 7.93 (1H, dd), 7.74 (1H, s), 7.58 (2H, m), 4.84 (2H, s), 3.64 (3H, s).

MP 202-3°C

- 10 c) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide.



- 15 Procedure as for Example 20 step b) using the product from Example 21 step b) (0.10 g).  
Yield 0.013g.


m/e 486 (M-1)<sup>-</sup>

<sup>1</sup>H NMR (DMSO) δ 8.54 (1H, s), 8.39 (1H, d), 8.02 (1H, d), 7.92 (1H, d), 7.74 (1H, d), 7.57 (2H, m), 7.26 (1H, m), 5.81 (1H, d), 4.83 (1H, m), 3.89 (3H, s), 3.42 (2H, m).


- 20 MP 188-90°C

### Example 22

**N-[5-[[2-Amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro benzenesulfonamide**




a) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.



Procedure as for Example 20 step b) using the product from Example 21 step a) (1.55 g).  
Yield 0.92 g  
 $m/e$  617 ( $M+1^+$ )

b) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide

15




Procedure as for Example 18 step a) using the product from Example 22 step a) (0.74 g).

Yield 0.32 g

m/e 635 (M+1<sup>+</sup>)

5 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.58 (2H, m), 7.98 (1H, d), 7.83 (1H, s), 7.75 (1H, d), 7.66 (1H, d), 7.32 (2H, m), 5.22 (2H, s), 5.10 (1H, m), 4.03 (1H, m), 3.98 (3H, m), 3.78 (2H, m), 3.64 (1H, m), 0.86 (2H, m), 0.00 (9H, s).

10 c) *N*-[5-[[2-Azido-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step b) using the product from Example 22 step b) (0.29g).

15 Yield 0.29g

m/e 642 (M+1<sup>+</sup>)

d) *N*-[5-[[2-Azido-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide




Procedure as for Example 1 step e) using the product from Example 22 step c) (0.29 g).

Yield 0.23 g

5 m/e 510 (M-1)<sup>-</sup>

e) *N*-[5-[[2-Amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro benzenesulfonamide



10


Procedure as for Example 18 step d) using the product from Example 22 step d) (0.23 g).

Yield 0.025g.


m/e 484 (M-1)<sup>-</sup>

15 <sup>1</sup>H NMR (DMSO) δ 8.63 (1H, s), 8.53 (1H, d), 8.00 (1H, d), 7.87 (1H, d), 7.80 (1H, d), 7.48 (1H, t), 7.39 (2H, m), 4.53 (1H, t), 3.85 (3H, s), 3.55 (2H, m).

MP 175-8°C

**Example 23****2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide**

5

**a) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide**

10

Procedure as for Example 16 step b) using 4-pyridinecarboxaldehyde (0.066 ml).


Yield 0.180g

$m/e$  617 ( $M+1^+$ )

15

**b) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide**





Procedure as for Example 1 step e) using the product from Example 23 step a) (0.14 g).

Yield 0.055 g


m/e 485 (M-1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO) δ 8.48 (2H, dd), 8.02 (1H, dd), 7.93 (1H, dd), 7.63 (1H, s), 7.57 (1H, t), 7.39 (2H, dd), 5.90 (1H, d), 4.81 (1H, m), 3.90 (3H, s), 3.46 (1H, dd), 3.35 (1H, dd).


MP 176-7°C

#### Example 24

**2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide**



a) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 16 step b) using 2-pyridinecarboxaldehyde (0.066 ml).

Yield 0.10g

5 m/e 617 (M+1<sup>+</sup>)

b) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide



10

Procedure as for Example 1 step e) using the product from Example 24 step a) (0.10 g).

Yield 0.016 g


m/e 485 (M-1<sup>-</sup>)

<sup>1</sup>H NMR (DMSO) δ 8.44 (1H, d), 8.02 (1H, d), 7.94 (1H, d), 7.73 (1H, t), 7.58 (2H, m),  
 15 7.49 (1H, d), 7.22 (1H, t), 5.82 (1H, s), 4.83 (1H, m), 3.91 (3H, s), 3.65 (1H, m), 3.35 (1H, m).

MP 143-5°C


### Example 25

**3-[[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2R)-2-hydroxypropanoic acid, methyl ester**



5

a) 3-[[5-[[[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-(2R)-2-hydroxypropanoic acid, methyl ester.




10

The product from Example 15 step a) (1.24 g) was dissolved in dry THF (10 ml) under an atmosphere of nitrogen and treated with a 1 M solution of potassium *tert*-butoxide in THF (2.3 ml), added dropwise. After stirring for 30 min the reaction was treated with (2S)-2-oxiranecarboxylic acid, methyl ester (1.0 ml) and allowed to stir for 20 hrs. The reaction mixture was poured into saturated aqueous ammonium chloride solution and extracted into ethyl acetate (x3). The combined ethyl acetate extracts were washed with water, brine and dried (MgSO<sub>4</sub>) and evaporated to leave an oil. The residue was purified by silica gel chromatography, eluting with 1:1 ethyl acetate:isohexane, to afford the sub-titled product as a colourless oil (0.23g).  
m/e 598 (M+1<sup>+</sup>)

20

b) 3-[[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2R)-2-hydroxypropanoic acid, methyl ester.



5

Procedure as for Example 1 step e) using the product from Example 25 step a) (0.23 g).  
Yield 0.012g.

m/e 466 (M-1)<sup>-</sup>

<sup>1</sup>H NMR (DMSO) δ 7.95 (1H, dd), 7.61 (1H, dd), 7.35 (1H, t), 7.19 (1H, s), 4.18 (1H, t),  
3.80 (3H, s), 3.50 (3H, s), 3.21 (1H, dd), 3.04 (1H, dd).


10

MP 88-90°C

### Example 26


*N*-[5-[[2-Amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

15



20

a) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step a) using the product from Example 24 step a) (0.70 g).

Yield 0.72 g

m/e 635 (M+1<sup>+</sup>)

5

b) *N*-[5-[[2-Azido-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide



10


Procedure as for Example 18 step b) using the product from Example 26 step a) (0.72g).

Yield 0.70 g

m/e 642 (M+1<sup>+</sup>)

15

c) *N*-[5-[[2-Azido-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide




Procedure as for Example 1 step e) using the product from Example 26 step b) (0.70 g).

Yield 0.34 g

m/e 510 (M-1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO) δ 8.57 (1H, m), 8.04 (1H, d), 7.94 (1H, d), 7.81 (1H, t), 7.65 (1H, s), 7.58 (1H, t), 7.47 (1H, d), 7.35 (1H, m), 4.94 (1H, t), 3.94 (3H, s), 3.75 (1H, m), 3.65 (1H, m).

d) *N*-[5-[[2-Amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



Procedure as for Example 18 step d) using the product from Example 26 step c) (0.15 g).

Yield 0.018g.

m/e 484 (M-1)<sup>+</sup>


<sup>1</sup>H NMR (DMSO) δ 8.54 (1H, d), 7.95 (1H, d), 7.76 (1H, t), 7.62 (1H, d), 7.45 (1H, d), 7.33 (2H, m), 7.19 (1H, s), 4.42 (1H, t), 3.79 (3H, s), 3.30 (2H, m).

MP 172-4°C

**Example 27**


***N*-[5-[[2-Amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide**

5



a) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide

10




Procedure as for Example 18 step a) using the product from Example 16 step b) (0.44 g).

Yield 0.45 g

$m/e$  638 ( $M+1^+$ )

15

b) *N*-[5-[[2-Azido-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step b) using the product from Example 27 step a) (0.72g).

Yield 0.455 g

5 m/e 645 (M+1<sup>+</sup>)

c) *N*-[5-[[2-Azido-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



10

Procedure as for Example 1 step e) using the product from Example 27 step b) (0.45 g).


Yield 0.36 g

m/e 513 (M-1)<sup>-</sup>

15

d) *N*-[5-[[2-Amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide





Procedure as for Example 18 step d) using the product from Example 27 step c) (0.36 g).  
Yield 0.038g.


5 m/e 489 (M+1<sup>+</sup>)

<sup>1</sup>H NMR (DMSO) δ 8.04 (1H, d), 7.94 (1H, d), 7.59 (2H, m), 7.05 (1H, s), 6.84 (1H, s),  
4.77 (1H, t), 3.95 (3H, s), 3.58 (3H, s), 3.5-3.7 (2H, m).

MP 187-9°C


#### 10 Example 28

**(2R)-2-Amino-3-[[3-chloro-5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-N-methylpropanamide**



15


a) *N,N'*-bis[(1,1-dimethylethoxy)carbonyl]-*N,N'*-dimethyl-L-cystinamide



A solution of *N,N'*-bis[(1,1-dimethylethoxy)carbonyl]-L-cystine (4.08g) in tetrahydrofuran (100 mL) was cooled to 0°C under nitrogen and isobutyl chloroformate (2.9 mL) was added dropwise followed by triethylamine (3.1 mL) dropwise. After 30 minutes at 0°C a 2.0M solution of methylamine in THF (20 mL) was added. After stirring at room temperature for 24 hours, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO<sub>4</sub>) and the solvent was evaporated to afford the subtitled product as a white solid (2.6 g).

m/e 467 (M+1<sup>+</sup>)

b) [(1*R*)-1-(Mercaptomethyl)-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester




To a suspension of the product from Example 28 step a) (2.15 g) in 1,1,1-trifluoroethanol (5 mL) and water (0.6 mL) was added dropwise tributylphosphine (2.25 mL) followed by triethylamine (0.10 mL). After stirring at room temperature for 24 hours, ethyl acetate and silica were added and the mixture evaporated. The residue was purified by silica gel chromatography, eluting with 1:1 ethyl acetate:isohexane, to afford the sub-titled product as a white solid (1.85 g).

m/e 233 (M-1<sup>-</sup>)

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.33 (1H, bs), 5.38 (1H, bs), 4.32 (1H, bs), 3.15 (1H, m), 2.85 (3H, d), 2.70 (1H, m), 1.55 (1H, t), 1.46 (9H, s).

c) [(1*R*)-1-[[[3-Chloro-5-[(2,3-dichlorophenyl)sulfonyl]]-[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester




5

Procedure as for Example 2 step a) using *N*-(5-bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (0.25 g) and [(1*R*)-1-(mercaptomethyl)-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.105 g).

10

Yield 0.24 g.

d) (2*R*)-2-Amino-3-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide



15

Procedure as for Example 1 step e) using the product from Example 28 step c) (0.24 g).  
Yield 0.03 g.

*m/e* 498 (*M*-1)<sup>+</sup>


<sup>1</sup>H NMR (DMSO) δ 8.25 (1H, d), 8.02 (1H, d), 7.63 (1H, d), 7.60 (2H, bs), 7.37 (1H, t), 3.80 (4H, m), 3.30 (2H, m), 2.55 (3H, d).

20

MP 150-5°C

**Example 29**


**(2*R*)-2-Amino-3-[[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]thio]-*N*-methylpropanamide**



5

a) [(1*R*)-1-[[[5-[[2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxy-3-methylpyrazinyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester

10




Procedure as for Example 2 step a) using the product from Example 11 step e) (0.25 g) and [(1*R*)-1-(mercaptomethyl)-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.11 g).

15

Yield 0.32 g.

b) (2*R*)-2-Amino-3-[[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]thio]-*N*-methylpropanamide



Procedure as for Example 1 step e) using the product from Example 29 step a) (0.32 g).

Yield 0.115 g.


m/e 478 (M-1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO) δ 8.06 (1H, dd), 7.80 (1H, m), 7.58 (1H, dd), 7.35 (1H, t), 3.77 (3H, s), 3.27 (2H, m), 2.93 (1H, m), 2.50 (3H, d), 1.87 (3H, s).


MP 68-80°C

### Example 30

***N*-[5-[[2-Amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide**



a) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 16 step (b) using thiazole-2-carboxaldehyde (1.0 g).

Yield 0.75 g

5 m/e 623 ( $M+1^+$ )

b) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide



10


Procedure as for Example 18 step a) using the product from Example 30 step a) (0.75 g).

Yield 0.77 g

m/e 639 ( $M+1^+$ )

15

c) *N*-[5-[[2-Azido-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step b) using the product from Example 30 step b) (0.77 g).

Yield 0.78 g

5 m/e 648 (M+1<sup>+</sup>)

d) *N*-[5-[[2-Azido-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



10


Procedure as for Example 1 step e) using the product from Example 30 step c) (0.78 g).

Yield 0.62 g

m/e 516 (M-1)<sup>-</sup>

15

e) *N*-[5-[[2-Amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



Procedure as for Example 18 step d) using the product from Example 30 step d) (0.62 g).  
Yield 0.15 g.


5 m/e 492 (M+1<sup>+</sup>)

<sup>1</sup>H NMR (DMSO)  $\delta$  8.16 (2H, bs), 7.98 (1H, d), 7.85 (1H, d), 7.77 (1H, d), 7.68 (1H, d), 7.41 (1H, t), 7.32 (1H, s), 4.77 (1H, t), 4.09 (1H, bs), 3.78 (3H, s), 3.4-3.6 (2H, m).

MP 168-9°C

#### 10 Example 31

***N*-[5-[[*(2R)*-2-Amino-3-hydroxypropyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide, monohydrochloride**



15

2,3-Dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g) and (4*S*)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylic acid 1,1-dimethylethyl ester (0.142g) were dissolved in dry 1,2-dimethoxyethane (5ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.026g). After stirring at ambient temperature overnight the  
20 reaction was poured into water and extracted twice with ethyl acetate. The organic extracts



were washed with brine, dried (MgSO<sub>4</sub>) and evaporated to give a pale yellow oil (0.413g). The oil was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (1ml). After stirring at ambient temperature overnight, methanol (5ml) was added and the solution was stirred for 1 hour. The mixture was diluted with dichloromethane, flash silica (5g) was added and the the solvents were removed *in vacuo*. The resulting powder was purified by flash chromatography on silica, eluting with 5% and 10% methanol in dichloromethane to afford a colourless residue (0.164g). After dissolving the residue in methanol and treating it with 4M HCl solution in 1,4-dioxane (1ml), the solvents were removed *in vacuo*. Trituration with diethyl ether afforded a solid that was removed by filtration and dried *in vacuo* at 40° to give the title compound as an off-white powder.

Yield 0.108g


m.p. 130-150°C (decomposes)

m/e 423/425 (M+1)<sup>+</sup>

<sup>1</sup>H NMR (D<sub>2</sub>O) 8.06 (1H, m), 7.95 (1H, m), 7.55 (2H, m), 4.69 (1H, m), 4.57 (1H, m), 4.02 (1H, m), 3.95 (3H, s), 3.90 (2H, m).

### Example 32

#### 2,3-Dichloro-N-[5-[[[(2S)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-benzenesulfonamide



2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g) and (4R)-2,2-dimethyl-1,3-dioxolane-4-methanol (0.079g) were dissolved in dry 1,2-dimethoxyethane (5ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.026g). After stirring at ambient temperature overnight the reaction was poured into water and extracted twice with ethyl acetate. The organic extracts were washed with brine, dried (MgSO<sub>4</sub>) and evaporated to give a colourless gum (0.230g). The gum was dissolved in dichloromethane (5ml) and

treated with trifluoroacetic acid (1ml). After stirring at ambient temperature for 2 hours, methanol (5ml) was added and the solution was stirred for 2.5 hours. More trifluoroacetic acid (2ml) was then added and the mixture was stirred for a further 3 hours. Flash silica (5g) was added and the the solvents were removed *in vacuo*. The resulting powder was purified by flash chromatography on silica, eluting with 5% methanol in dichloromethane to afford a white foam (0.055g). Further purification by reversed phase preparative hplc gave the title compound as a white foam.


Yield 0.026g

m/e 424/426 (M+1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 7.95 (1H, m), 7.85 (1H, m), 7.49 (1H, m), 7.34 (1H, s), 4.93 (1H, d), 4.63 (1H, t), 4.23 (1H, m), 4.08 (1H, m), 3.80 (3H, s), 3.76 (1H, m), 3.40 (2H, m).

### Example 33

**2,3-Dichloro-N-[5-[[*(2R)*-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-benzenesulfonamide**



2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g) and (4*S*)-2,2-dimethyl-1,3-dioxolane-4-methanol, (0.080g) were dissolved in dry 1,2-dimethoxyethane (5ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.026g). After stirring at ambient temperature overnight the reaction was poured into water and extracted twice with ethyl acetate. The organic extracts were washed with brine, dried (MgSO<sub>4</sub>) and evaporated to give a colourless gum (0.346g). The gum was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (1ml). After stirring at ambient temperature for 2 hours, methanol (5ml) was added and the solution was stirred for 2.5 hours. More trifluoroacetic acid (2ml) was then added and the mixture was stirred for a further 3 hours. Flash silica (5g) was added and the the solvents were removed *in vacuo*. The resulting powder was

purified by flash chromatography on silica, eluting with 4% methanol in dichloromethane to afford a white foam (0.060g). Further purification by reversed phase preparative hplc gave the title compound as a white foam.


Yield 0.035g

5 m/e 424/426 (M+1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 7.94 (1H, m), 7.74 (1H, m), 7.42 (1H, m), 7.18 (1H, s), 4.89 (1H, d), 4.61 (1H, t), 4.16 (1H, m), 4.00 (1H, m), 3.78 (3H, s), 3.75 (1H, m), 3.39 (2H, m).

#### Example 34

10 ***N*-[5-[[*(2R)*-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide**



15 *N*-(5-Bromo-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g), [(1*R*)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester (0.133g) and caesium carbonate (0.166g) in acetonitrile (5ml) were stirred at ambient temperature overnight. The reaction was poured into a mixture of water and brine and extracted twice with ethyl acetate. The organic

20 extracts were washed with brine, dried (MgSO<sub>4</sub>) and evaporated to give a yellow gum (0.385g). The gum was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (2.5ml). After stirring at ambient temperature for 1 hour the solvents were removed *in vacuo* and the residue was purified by reversed phase preparative hplc to afford the title compound as a pale orange powder.


25 Yield 0.062g

m/e 491/493 (M+1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 8.05 (1H, m), 7.95 (1H, m), 7.63 (1H, s), 7.59 (1H, m), 5.11 (1H, t), 3.97 (3H, s), 3.78 (2H, broad d), 2.26 (3H, s).

### Example 35

5 *N*-[5-[[*(2R)*-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulfonamide




10 *N*-(5-Bromo-3-methoxy-6-methylpyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.251g), [(1*R*)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester (0.143g) and caesium carbonate (0.184g) in acetonitrile (5ml) were stirred at ambient temperature overnight. More [(1*R*)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid  
15 1,1-dimethylethyl ester (0.082g), caesium carbonate (0.089g) and acetonitrile (5ml) were added and the mixture was stirred at ambient temperature for 2 more days. The reaction was poured into a mixture of water and brine and extracted three times with ethyl acetate. The organic extracts were washed with brine, dried (MgSO<sub>4</sub>) and evaporated to give a brown gum (0.441g). The gum was dissolved in dichloromethane (5ml) and treated with  
20 trifluoroacetic acid (2.5ml). After stirring at ambient temperature for 2.75 hours, flash silica (5g) was added and the solvents were removed *in vacuo*. The resulting powder was purified by flash chromatography on silica, eluting with 2% and 5% methanol in dichloromethane to afford a pale brown foam (0.095g). Further purification by reversed phase preparative hplc afforded the titled compound as a pale yellow powder.  
25 Yield 0.021g  
m/e 505/507 (M+1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 8.09 (1H, d), 7.83 (1H, d), 7.52 (1H, t), 4.48 (1H, t), 3.85 (3H, s), 3.45-3.60 (2H, m), 2.22 (3H, s), 1.95 (3H, s).

### Example 36

5 ***N*-[5-[[*(2R)*-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide**



10 A solution of *N*-(5-Bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (0.203g), [(1*R*)-2-mercapto-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester (0.158g) and *N,N*-diisopropylethylamine (0.060ml) in *N*-methylpyrrolidinone (3ml) was stirred at 50° overnight. The reaction mixture was concentrated *in vacuo* to give a brown residue that

15 was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (2.5ml). After stirring at ambient temperature for 1.25 hours the solvents were removed *in vacuo* and the residue was purified by reversed phase preparative hplc to afford a white solid. Recrystallisation from aqueous methanol gave the title compound an off-white powder. Yield 0.035g

20 m/e 527 (M+1)<sup>+</sup>

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) 8.24 (1H, br), 8.02 (1H, d), 7.70 (1H, d), 7.42 (1H, t), 4.94 (1H, t), 3.86 (3H, s), 3.66 (1H, m), 3.53 (1H, m), 2.29 (3H, s).

### Pharmacological Analysis

25

FMAT Whole cell binding assay

## Cells

CHO-K1 cells stably expressing the human recombinant CCR4 receptor (Euroscreen; Brussels, Belgium) were cultured in NUT.MIX.F\_12(HAM) medium with glutamax-1, containing 10% (v/v) foetal bovine serum and 400  $\mu\text{g ml}^{-1}$  geneticin.

Cells were harvested at approximately 70% confluence by treatment with a cell dissociation buffer, and seeded at  $5 \times 10^3$  cells/100 $\mu\text{l}$  culture medium into wells of a black Costar clear-bottomed 96-well microtitre plates. Plates were incubated overnight at 37°C in 5%  $\text{CO}_2$  and used the following day.

## ASSAY

Before use, the cell plates were washed twice with 100  $\mu\text{l}$  Hanks balanced salt solution (HBSS). To each well was then added 65 $\mu\text{l}$  of HBSS, 10  $\mu\text{L}$  of 10% DMSO in HBSS  $\pm$  test compound and then 25  $\mu\text{L}$  of 2.8 nM FB-MDC (Applied Biosystems). This fluorescent probe was prepared from a 10 $\mu\text{M}$  stock in 0.08% (v/v) TFA/16% (v/v) acetonitrile, diluted into HBSS.

After two hours incubation in the dark at room temperature, the plates were analysed in an FMAT8100 reader (Applied Biosystems) to measure fluorescence that was associated with binding of FB-MDC to the cells. Compound activity was determined as an  $\text{pIC}_{50}$  [ $\log(\text{concentration of compound that results in 50\% inhibition})$ ], comparing fluorescence in control and background wells.

## Typical Data

Fluorescence (ctrl) = 1200  
Fluorescence (bkg) = 0

The compounds of the examples all have a  $\text{pIC}_{50}$  of greater than 5.0.

Data for specific compounds is given below.

	Mean
Example 4 $\text{pIC}_{50}$	6.2


Example 15

pIC<sub>50</sub>

6.4

## CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:



in which:

Ar<sup>1</sup> is phenyl or thienyl, each of which is optionally substituted by one to three substituents R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> selected from halogen, cyano, CF<sub>3</sub>, OCF<sub>3</sub>, OC<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkyl;

R<sup>4</sup> is C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group; or

OC<sub>1-6</sub> alkylR<sup>11</sup>, or OC<sub>2-6</sub> alkyl-X-R<sup>11</sup> where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR<sup>14</sup>R<sup>15</sup>, SR<sup>13</sup>, S(O)<sub>2</sub>R<sup>13</sup>, S(O)R<sup>13</sup> or COR<sup>13</sup>;

one of R<sup>5</sup> or R<sup>6</sup> is XCH<sub>2</sub>C<sub>1-4</sub> alkyl where the alkyl group is substituted at any position by the two groups R<sup>11</sup> and either NR<sup>14</sup>R<sup>15</sup> or hydroxy, or R<sup>5</sup>/R<sup>6</sup> is XR<sup>16</sup> where R<sup>16</sup> is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O, and R<sup>16</sup> is substituted by R<sup>11</sup>;

and the other is hydrogen, halogen, amino, NHC<sub>1-6</sub> alkyl, N(C<sub>1-6</sub> alkyl)<sub>2</sub>, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkyl optionally substituted by one or more fluoro or hydroxyl groups;

X is NR<sup>13</sup>, O, S, S(O), S(O)<sub>2</sub>, or a bond;

R<sup>11</sup> is an aryl group or a 5-7 membered heteroaromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, which aryl group or heteroaromatic ring can be optionally substituted by 1-3 groups selected from halogen, C(O)NR<sup>14</sup>R<sup>15</sup>, C(O)OR<sup>12</sup>, hydroxy, =O, =S, CN, NO<sub>2</sub>, COR<sup>13</sup>, NR<sup>14</sup>R<sup>15</sup>, X(CH<sub>2</sub>)<sub>q</sub>NR<sup>14</sup>R<sup>15</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>14</sup>R<sup>15</sup>, (CH<sub>2</sub>)<sub>n</sub>OH, SR<sup>13</sup>, S(O)R<sup>13</sup>, S(O)<sub>2</sub>R<sup>13</sup>



C<sub>1-6</sub> alkyl-X-C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR<sup>14</sup>R<sup>15</sup>, SR<sup>13</sup>, S(O)R<sup>13</sup>, S(O)<sub>2</sub>R<sup>13</sup>; or

5 R<sup>11</sup> is C(O)NR<sup>14</sup>R<sup>15</sup>, C(O)OR<sup>12</sup>, CH<sub>2</sub>OR<sup>12</sup>

R<sup>12</sup> and R<sup>13</sup> are independently hydrogen or C<sub>1-6</sub> alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;

10 R<sup>14</sup> and R<sup>15</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, (CH<sub>2</sub>)<sub>q</sub>OH or (CH<sub>2</sub>)<sub>q</sub>NH<sub>2</sub>,

or R<sup>14</sup> and R<sup>15</sup> together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl-OH, or hydroxy; and

n is 1, 2, 3, 4 or 5; and

q is 2, 3, 4, 5 or 6,

20

- provided that where X is a bond then R<sup>5</sup>/R<sup>6</sup> is not XCH<sub>2</sub>C<sub>1-4</sub>alkylR<sup>11</sup>.

2. A compound according to claim 1 in which Ar<sup>1</sup> is phenyl optionally substituted by one or more halogen atoms.

25

3. A compound according to claim 1 or 2 in which R<sup>4</sup> is methoxy.

4. A compound according to any one of claims 1 to 3 in which R<sup>5</sup> is XCH<sub>2</sub>CH(R<sup>11</sup>)NR<sup>14</sup>R<sup>15</sup> where R<sup>11</sup> is CO<sub>2</sub>Me or CONHMe or a 5 or 6-membered heterocycle and NR<sup>14</sup>R<sup>15</sup> is NH<sub>2</sub> or NHMe and X is S or O.

30

5. A compound according to any one of claims 1 to 4 in which R<sup>6</sup> is hydrogen, chloro or methyl.

35 6. A compound according to any one of claims 1 to 5 in which X is NR<sup>13</sup>, O, S, S(O) or S(O)<sub>2</sub>.

7. A compound of formula (I) selected from:

S-[5-[[[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester

- S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester  
S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine  
(2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide  
5 (2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide  
(2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N,N*-dimethylpropanamide  
*N*-[5-[(2*R*)-2-amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichloro  
10 benzenesulfonamide  
S-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester  
S-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine  
*N*-[5-[(2*R*)-2-amino-3-hydroxypropyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-  
15 dichlorobenzenesulfonamide  
S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, methyl ester  
S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine,  
*N*-(2-Aminoethyl)-S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-  
20 cysteine, ethyl ester  
*N*-[5-[(2*R*)-2-amino-2-phenylethoxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide  
2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide,  
2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide, potassium salt  
25 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide  
*N*-[5-[[2-amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide  
30 2,3-dichloro-*N*-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl] benzenesulfonamide  
2,3-dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl] benzenesulfonamide  
2,3-dichloro-*N*-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl] benzenesulfonamide  
35

*N*-[5-[[2-amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro benzenesulfonamide

2,3-dichloro-*N*-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide

5 2,3-dichloro-*N*-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide

3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2*R*)-2-hydroxypropanoic acid, methyl ester

10 *N*-[5-[[2-amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

*N*-[5-[[2-amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

(2*R*)-2-amino-3-[[3-chloro-5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide

15 (2*R*)-2-amino-3-[[5-[[[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]thio]-*N*-methylpropanamide

*N*-[5-[[2-amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

20 *N*-[5-[[[(2*R*)-2-Amino-3-hydroxypropyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide, monohydrochloride

2,3-Dichloro-*N*-[5-[[[(2*S*)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]benzenesulfonamide


2,3-Dichloro-*N*-[5-[[[(2*R*)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]benzenesulfonamide

25 *N*-[5-[[[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

*N*-[5-[[[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulfonamide

30 *N*-[5-[[[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide  
and pharmaceutically acceptable salts thereof.

8. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed any one of claims 1 to 7 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 5 9. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 for use in therapy.
10. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 to 7 in the manufacture of a medicament for use in therapy.
- 10 11. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 to 7 in the manufacture of a medicament for use as a CCR4 antagonist.
- 15 12. A compound of formula (I) for use in the treatment of a disease where modulation of CCR4 activity is beneficial.
13. A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a  
20 therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed any one of claims 1 to 7.
14. A method according to claim 13 in which the chemokine receptor belongs to the CCR chemokine receptor subfamily.
- 25 15. A method according to claim 13 or 14 in which the chemokine receptor is the CCR4 receptor.
16. A method of treating an inflammatory disease in a patient suffering from, or at risk of,  
30 said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7.
17. A method according to claim 16 wherein the disease is asthma.
- 35 18. A process for the preparation of a compound of formula (I) which comprises either  
(a) reacting of a compound of formula (II):




(II)

, wherein  $\text{Ar}^1$ ,  $\text{R}^4$  and  $\text{R}^6$  are as defined above, P is a protecting group and X is a leaving group,

with a compound  $\text{R}^5\text{---H}$  in the presence of a base, and optionally thereafter,


- removing any protecting groups
- forming a pharmaceutically acceptable salt:

(b) where the compound of formula (I) is of formula (Ia)



(Ia)

, wherein  $\text{Ar}^1$ ,  $\text{R}^4$ ,  $\text{R}^6$  and  $\text{R}^{11}$  are as defined above, reacting a compound of formula (X)



(X)

with a reducing agent such as triphenylphosphine in the presence of water, and optionally thereafter,

- removing any protecting groups
- forming a pharmaceutically acceptable salt.

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/SE2004/000850**

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **13-17**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see next sheet**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/SE2004/000850**

Claims 13-17 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000850

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC7: C07D 241/20, C07D 403/12, C07D 417/12, C07D 401/12, C07D 413/12, A61K 31/4965, A61K 31/497, A61P 11/06, A61P 29/00 According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) <b>IPC7: C07D, A61K, A61P</b> Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched <b>SE,DK,FI,NO classes as above</b> Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) <b>EPO-INTERNAL, CHEM. ABS DATA, PAJ</b>				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	WO 0224665 A1 (ACTELION PHARMACEUTICALS LTD), 28 March 2002 (28.03.2002) --	1-18		
A	WO 0230357 A2 (CHEMOCENTRYX, INC.), 18 April 2002 (18.04.2002) --	1-18		
A	US 6420567 B1 (CHENGDE WU ET AL), 16 July 2002 (16.07.2002) --	1-18		
PX	WO 03051870 A1 (ASTRAZENECA AB), 26 June 2003 (26.06.2003) --	1-18		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; border: none;">           * Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier application or patent but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 50%; vertical-align: top; border: none;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search <b>29 Sept 2004</b>		Date of mailing of the international search report <b>05-10-2004</b>		
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer <b>Anna Sjölund/Eö</b> Telephone No. +46 8 782 25 00		

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000850

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	WO 03059893 A1 (ASTRAZENECA AB), 24 July 2003 (24.07.2003)  -- -----	1-18

## INTERNATIONAL SEARCH REPORT

Information on patent family members

03/09/2004

International application No.

PCT/SE 2004/000850

WO	0224665	A1	28/03/2002	AU	1217102	A	02/04/2002
				BR	0114082	A	22/07/2003
				CA	2423351	A	28/03/2002
				EP	1322624	A	02/07/2003
				HU	0303364	A	01/03/2004
				IL	154364	D	00/00/0000
				NO	20031332	A	24/03/2003
				US	20040102464	A	27/05/2004

WO	0230357	A2	18/04/2002	AU	1346602	A	22/04/2002
				AU	1346702	A	22/04/2002
				CA	2425259	A	18/04/2002
				US	20020132836	A	19/09/2002
				US	20020173524	A	21/11/2002
				US	20040039035	A	26/02/2004
				WO	0230358	A	18/04/2002

US	6420567	B1	16/07/2002	US	6632829	B	14/10/2003
				US	20020091272	A	11/07/2002
				US	20030208084	A	06/11/2003
				AP	9901471	D	00/00/0000
				AT	270669	T	15/07/2004
				AU	736269	B	26/07/2001
				AU	4505997	A	17/04/1998
				BR	9711550	A	18/01/2000
				CA	2261760	A	02/04/1998
				CN	1231664	A	13/10/1999
				CZ	9900854	A	16/06/1999
				DE	69729803	D	00/00/0000
				EA	4146	B	00/00/0000
				EP	0946552	A,B	06/10/1999
				EP	1342721	A	10/09/2003
				IL	128145	D	00/00/0000
				JP	2000507607	T	20/06/2000
				JP	2002308875	A	23/10/2002
				KR	2000048681	A	25/07/2000
				NO	991388	A	27/05/1999
				NZ	334797	A	23/02/2001
				OA	11024	A	06/11/2001
				PL	332323	A	30/08/1999
				SK	36599	A	14/02/2000
				TR	9900705	T	00/00/0000
				US	5962490	A	05/10/1999
				US	6331637	B	18/12/2001
				WO	9813366	A	02/04/1998

WO	03051870	A1	26/06/2003	SE	0104474	D	00/00/0000
				CA	2466491	A	30/05/2003
				SE	0202139	D	00/00/0000

WO	03059893	A1	24/07/2003	DE	10296133	T	15/04/2004
				SE	0200119	D	00/00/0000
				US	20040113409	A	17/06/2004
				EP	1436058	A	14/07/2004
				SE	0201857	D	00/00/0000